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ABSTRACT 
 This paper analyzes the impact of mergers and acquisitions (M&A) activities 
in research-based pharmaceutical companies, specifically the impact of R&D 
expenditure, profitability, and sales revenue on firms’ productivity, R&D intensity, in 
pharmaceutical industries following M&A activities. The model was estimated using 
annual data, gathered from seven large research-based pharmaceutical companies pre 
and post-M&A, during the period 2003 until 2010. The regression analysis method 
uses a fixed effect method with generalized least square (GLS) analysis. The result 
further shows that following M&A activities, firms’ one-year lagged R&D 
expenditure (t-1) and lagged profitability (t-1) to be positive in increasing 
significantly the firms’ amount of R&D intensity in research-based pharmaceutical 
industries, while, surprisingly firms’ one-year lagged sales revenue (t-1) have a 
negative impact in increasing significantly the firms’ amount of R&D intensity in 
research-based pharmaceutical industries.  
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1.  Introduction 
 During the last decade, mergers and acquisitions have an increasing trend in 
pharmaceutical companies. There are many triggering factors why these M&A occur 
including the high competition in pharmaceutical industry, and driven by other 
factors such as patents expiration of blockbuster products, the slowing development 
of new therapeutic and the newest technology, expansion of market share, pressure of 
stock market among other things. Another common reason includes consolidation 
research and development, manufacturing, sales, and marketing, leading to more 
resource effectiveness and efficiency (Danzon, Epstein, and Nicholson, 2003). 
In order to expand the business of pharmaceutical drugs and to generate new 
molecular entities, many research-based companies take the liberty of undergoing 
M&A. Using the M&A vehicle, research-based pharmaceutical companies, suddenly 
accumulate new resources that they can use to expand their pipeline products, as well 
as a means to enter and strengthen in newer therapeutic areas. Companies which have 
gone through M&A are expected to rapidly generate high return, so that they will be 
able to accumulate excess cash for further rapid growth (Davidson and Greblov, 
2005). Clifford Kalb (2006) presented another three main point advantage of M&A 
activities in the pharmaceutical companies: 1) economics of scale, to include those 
aspects in sales/marketing power, financial power, production capacity, and market 
share; 2) the existence of synergies in research portfolio, geography, sales, and 
production; as well as 3) combined R&D budget of the respected to ease access of 
technologies, eliminate redundancies, and focus within therapeutic categories. 
Table 1 shows several mergers and acquisitions conducted by research-based 
pharmaceutical companies from period 2003 until 2010. From that time period, one 
of the biggest M&As have been ones conducted by Roche. Roche acquired 
Genentech for $46.8 in 2009, and then decided to acquire the remaining 44 percent of 
the company (Shantikumar, 2009). By acquiring Genentech, Roche has a strategy that 
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it has no intentions of moving into generic drug or consumer product business, as 
Pfizer and Novartis (Shantikumar, 2009). 
 
Table 1: Several M&A in Research-Based Pharmaceutical Companies,  
Period 2003 - 2010 
Company Year M&A 
Roche 2009 Genentech 
Sanofi-Aventis 2004 Aventis 
 
2005 Hoechst AG 
  2009 BiPar Sciences Inc 
  2010 Genzyme 
Astrazeneca 2006 
KuDOS Pharmaceuticals; Cambridge Antibody 
Tech. Grp. 
 2007 Arrow Therapeutics Ltd; MedImmune Inc. 
  2010 Novexel SA 
Merck 2005 Aton Pharma Inc. 
  2006 Sirna 
 
2009 Schering-Plough 
Eli Lilly 2008 ImClone 
  2010 Alnara Pharmaceuticals, Avid Radiopharmaceuticals 
Takeda 2008 Millenium Pharmaceuticals 
Teva 2004 SICOR, Inc. 
 2006 Ivax Corporation 
 2008 CoGenesys Inc.; Bentley Pharmaceuticals, Inc. 
 2009 Barr Pharmaceuticals 
 
Through M&A with Genentech, Roche was able to acquire biotechnology 
product as Rituxan, Avastin, Herceptin, and Tarceva. Other companies are also active 
in M&A activities; Sanofi-Aventis performed M&A with Hoechst, Synthelabo, and 
Aventis (which later changed their name) for $65.5 billion, followed by acquisition of 
biotech companies BiPar Sciences Inc, and Genzyme for $18.5 billion. Astrazeneca 
followed the acquisition with several biotechnology companies, as KuDOS 
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Pharmaceuticals which focuses on discovery and development of drugs based upon 
the science of DNA for cancer treatment; Cambridge Antibody Tech. Grp which 
focuses on antibody therapeutics, using phage display and ribosome display 
technology; Arrow Therapeutics Ltd engages in the discovery and development of 
anti-viral therapies; MedImmune Inc. which works to boost the immune systems of 
babies and grown-ups; and lastly, Novexel SA engages in the discovery and 
development of antibacterial and antifungal agents. Merck acquired Sirna in 2006 for 
$1.1 billion in order to get hold of new RNAi technology, and also acquired 
Schering-Plough for $41 billion in 2009, to strengthen them in pharmaceutical 
products. Lilly acquired ImClone in 2008 for $6 billion, to get access to the 
biotechnology product for oncology Erbitux. Bristol-Myers Squibb acquired Medarex 
to develop monoclonal antibodies for $2.4 billion, and continued with acquiring 
Zymogenetics Inc. Takeda also follow other large companies with the acquisition of 
Millenium Pharmaceuticals for $8.8 billion, and added their oncology product, 
Velcade, into their product portfolio. Lastly, Teva also acquired biopharmaceutical 
company, CoGenesys Inc., which engages in discovery and development of 
biopharmaceuticals and long-acting medicines for various therapeutic areas. At this 
time, the company is known as Teva Biopharmaceuticals USA, Inc.  
Theoretically, productivity in pharmaceutical company’s post M&A can be 
increased by the combined R&D expenditure and increasing the innovation activity in 
the company. This activity will increase the net profit of the combined company, and 
will also lead to an increase in new source of funds for R&D activities within the 
company. F. M. Scherer (2001) said that in pharmaceutical businesses, profits are 
important stimuli and become a source of funding for research and development 
activity, which in turn leads to a stream of new health-enhancing products. The 
strategies to increase R&D investment in pharmaceutical companies depend on the 
profitability they earned in the previous period, if the profits they earn in previous 
periods increase, then they can invest more in R&D activities, and if the profits they 
earned during the previous period decrease, then they cannot invest more in their 
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R&D activities, and expectations of profits to be earned in the future will be reduced. 
This result will be driving high R&D intensity of a firm. Kotabe (1990) stated that 
there is a positive relationship between R&D intensity and firm’s performance (citing 
by Andras and Srinivasan, 2003). 
There are several plausible reasons that describe why pharmaceutical 
companies need a lot of funds for R&D activities. Firstly, there is much patent 
expiration which in turn requires the company to soon provide fresh funds for R&D 
to boost their pipeline of innovative new drugs. Indeed, patent expiration was, in 
actual, one of the main reasons that prompted pharmaceutical companies to undergo 
M&A at the first place. In this regard, M&As were performed to compensate for the 
revenue loss (which will also result in reduced R&D funds and R&D intensity later) 
due to existing blockbuster drug patent expiration in the near future (Shantikumar, 
2009). According to Shields (2011), between 2007 until 2012, the top 50 
pharmaceutical companies are facing patent expiration on $115 billion worth of 
drugs. Second, the companies must have the access to fresh funds that allow them to 
pay for increased cost of doing research. According to Shantikumar (2009), the cost 
incurred to bringing a new drug to the market has increased to nearly $1 billion in 
2008 from about $100 million in 1990.  
After the drugs are marketed, the company could earn revenue from the drugs 
sales. More products are produced through R&D activities, and then the probability 
sales revenue obtained by the company would be greater. In fact previously, we 
reported that R&D intensity in pharmaceutical companies is always related to how 
much companies invest in R&D, relative to their sales revenue (Simanjuntak and 
Tjandrawinata, 2011). Chao and Kavadias (2009) found that a key metric for the 
assessment of innovative activity at the firm level is research and development 
intensity, defined as the ratio of a firm’s R&D investment to its revenue. This is 
because when there was an increase in R&D spending, the increase was always 
associated with an increase in sales revenue. When the acquired company’s profit 
increased by increasing the value of sales revenue, the company found that it is more 
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profitable for firms to invest their incremental dollars of sales revenue in their own 
drug research (A US Congressional Budget Office Study, 2006). Gee (1981) found 
that industries that devote a larger percentage of sales to R&D are generally more 
profitable and competitive. In addition, Davidson and Greblov (2005) proposed that 
when calculated based on R&D intensity of a pharmaceutical company, the amount of 
the investments conducted by pharmaceutical company against their R&D activities 
will determine the characteristic and the size of that company. Also from R&D 
intensity, innovation activities of a firm can be seen.  
Every year, R&D spending has grown faster, because nowadays many 
companies choose to invest their money in R&D activity, to gain future revenue in 
appropriate to their expectation. This makes the R&D intensity to increase annually. 
Pharmaceutical companies that perform M&A expect consolidation in terms of sales 
and marketing will be able to obtain greater benefits through the enhancement on 
market share and this will result in greater sales revenue, thus they can invest more in 
research activities. Therefore, it can be concluded that such companies will get hold 
of new sources of funds that can be utilized to perform greater R&D activities. 
Besides that, by doing M&A, there is a consolidation of knowledge, human capital, 
and technology from different companies. Rogers (2001) suggest that the synergy 
between these activities will lead to higher productivity, thus the company will switch 
their funds to R&D, and will lead to an enhancement in R&D intensity.  
Besides information mentioned above, there are still other pros and cons 
regarding mergers and acquisitions in the pharmaceutical industries. Jensen (1987) 
stated that total spending on R&D is increasing concurrent with the wave of mergers 
and acquisitions. Bronwyn Hall (1988) finds there is no difference in pre- and post-
mergers R&D performance in firms who are involved in mergers, but for firms with 
the highest propensity to merge, those that did merge experienced more rapid post-
merger growth that those that did not merge (citing by Danzon, Epstein, and 
Nicholson, 2003). Martynova, Oosting, and Renneboog (2006) said that the 
acquirer’s leverage prior takeover seems to have no impact on the post-merger 
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performance of the combined firm. They also concluded that acquisitions of relatively 
large targets result in better profitability of the combined firm subsequent to the 
takeover, whereas acquisitions of a small target lead to a profitability decline. 
Maggon (2011) suggested that if a company was acquired for its R&D pipeline and 
development project or platform technology, it will impact on the failure of the 
acquiring company to derive full benefits and most of the projects would later be 
discontinued or terminated. This raises the question about the effectiveness of the 
mergers and acquisitions in the pharmaceutical industries. 
The main purpose of this study is to examine the role of M&A in company 
productivity by looking at the influence of firms’ lagged R&D expenditure, firms’ 
lagged profitability, and firms’ lagged sales revenue on firms’ R&D intensity of 
research-based pharmaceutical companies, which have gone through mergers and 
acquisitions. In this paper, we expect to observe our hypotheses, as follows: 
Hypothesis 1: Firms’ amount of R&D expenditure is positively associated with firms’ 
amount of R&D intensity. 
Hypothesis 2: Firms’ amount of profitability is positively associated with firms’ 
amount of R&D intensity. 
Hypothesis 3: Firms’ amount of sales revenue is positively associated with firms’ 
amount of R&D intensity. 
Following hypothesis formulation, a model was devised to investigate the 
relation of each hypothesis on the model of the productivity in the research-based 
pharmaceutical companies that have gone through M&A, as measured by R&D 
intensity. 
 
2.  Methodology and Measurement 
2. 1  Samples and Data Collection  
 Samples used in this study consist of seven multinational research-based 
pharmaceutical companies. This study used financial data obtained from annual 
financial reports of each research-based pharmaceutical company. The research-based 
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pharmaceutical companies included in this study were Roche, Sanofi-Aventis, 
AstraZeneca, Merck, Takeda, Lilly, and Teva. The variables included in the data 
collection were research and development expenditure, profitability, sales revenue, 
and research and development intensity. Since there are one-year lags in R&D 
expenditure (t-1), profitability (t-1), and sales revenue (t-1) variable, then the whole 
panel data observation becomes 48 observations and unbalanced, because of missing 
observations. The definitions and measurements of these constructs were further 
defined as follows: 
1. R&D Expenditure  
This study uses total R&D expenditure data as the independent variable of our 
model. Total research and development expenditure data is obtained from the 
income statement contained in the published annual financial statements, from 
each research-based pharmaceutical company. The R&D expenditure data used 
in our model was one-year lagged (t-1) R&D expenditure.  
2.  Profitability 
The data used is the profit after tax as the proxy for profitability, which is 
obtained from the income statement contained in the annual financial statements. 
In this study, profitability variable uses the profitability data of each 
pharmaceutical company that is one-year lagged (t-1) profitability. 
3.  Sales Revenue (SR) 
Total sales revenue was also used, as the independent variable data was obtained 
from the income statement contained in the annual financial statement of each 
pharmaceutical company. The sales revenue data used in our model was one-
year lagged (t-1) sales revenue. 
4.  R&D Intensity (RDI) 
Research and development intensity was the ratio of a company’s investment in 
research and development compared to the firm’s sales. According to Davidson 
and Greblov (2005), the magnitude of R&D intensity can determine the 
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characteristics of a pharmaceutical company. In this study, R&D intensity was 
derived as follows: 
        
It is reasonable to use R&D intensity as a proxy of firm’s productivity to see how 
big the research productivity is for a company. 
 
2. 2  Methodology and Models 
 This study was conducted by using regression analysis methods using fixed 
effect models, with generalized least square (GLS) method. Because of the equation 
below containing heteroscedastic error, the GLS method (with White 
heteroscedasticity) was employed to transform it to homoscedastic error in order to 
satisfy the Gauss-Markov assumptions. GLS was necessary to correct for within-
group and contemporaneous serial correlation (Vernon, Golec, Lutter, and Nardinelli, 
2006). The purpose of this study is to examine the relationship between firms’ one-
year lagged R&D expenditure (t-1), firms’ one-year lagged profitability (t-1), firms’ 
one-year lagged sales revenue, and firms’ R&D intensity, in the period 2003 until 
2010. The model equations used in this study was: 
     (1) 
Logarithmic transformation is used for all the variables in the model, because 
with logarithmic value, an elasticity value is obtained, and therefore it would make it 
easier for us to see clearly and to interpret the correlation between the dependent and 
independent variables. In the model described above, the coefficient of each 
independent variable (slope) shows the elasticity of firms’ one-year lagged R&D 
expenditure, one-year lagged profitability, and one-year lagged sales revenue to R&D 
intensity respectively. This shows the percentage change in the firms’ R&D intensity, 
for one percentage change in the firms’ one-year lagged R&D expenditure, 
profitability, and sales revenue. 
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3. Result 
 Through the estimation using pooled regression model, the values of the 
coefficient estimates have been obtained. Table 2 depicts the result of regression 
analysis. 
 
Table 2: Result of Regression Analysis Based on a Panel Data of Seven Research-
Based Pharmaceutical Companies, Period 2003 – 2010 
Dependent Variable: RDI? 
Cross-sections included: 7 
Total pool (unbalanced) observations: 48 
Variable Coefficient Std. Error t-Statistic Prob.   
C 0.270287 0.091304 2.960306*** 0.0053 
LOG(RD?(-1)) 0.106928 0.018667 5.728109*** 0.0000 
LOG(PROFIT?(-1)) 0.007047 0.002087 3.376620*** 0.0017 
LOG(SR?(-1)) -0.103154 0.021717 -4.749875*** 0.0000 
R-squared 0.947935       
Adjusted R-squared 0.935604       
F-statistic 76.8726       
Durbin-Watson stat 2.183543       
 Source: The model was processed by Eviews5.1 
 Two-tail significance levels : 
          * Significant at level 10 % 
          ** Significant at level 5 % 
          *** Significant at level 1 % 
 In this case, the coefficient of firms’ one-year lagged R&D expenditure (t-1); 
firms’ one-year lagged profitability (t-1), and firms’ one-year lagged sales revenue (t-
1) were transformed into logarithmic scale, in order to get an elasticity measurement 
within the coefficient value of the slopes, while firms’ R&D intensity was not 
transformed into logarithmic scale, since the value is a result of the ratio of R&D 
expenditure to revenue. 
 The parameter estimates of the model are shown in Table 2. The fitness of the 
model as measured by R-squared measurement having a value of 0.94 is acceptable 
and the estimated coefficients are generally statistically significant. We have 
conducted and examined different models, varying on time period and found that this 
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particular model and period holds the best regressions throughout. As seen in Table 2 
(based on our model above), a positive and statistically significant relationship 
existed between log(RD?(-1)) and RDI?. The reason of the use of past R&D 
expenditure is due to its effect on firm’s capital stock, which in turn will affect the 
amount of current R&D expenditure and the productivity in firms. A positive 
relationship between firms’ one-year lagged of R&D expenditure and firms’ R&D 
intensity, suggesting that enhancement in firms’ one-year lagged of R&D expenditure 
could increase their current R&D intensity. Our elasticity estimates showed an 
amount of 0.11 percent, which means that a one percent increase (decrease) in firms’ 
one-year lagged of R&D expenditure, will be accompanied by 0.11 percent increase 
(decrease) in firms’ ratio of R&D expenditure to total sales revenue. The result 
obtained by the regression, consistent with the assumption that the M&A companies 
will result in high productivity (because there is consolidation in research activity), 
therefore will result in increase in R&D spending in pharmaceutical companies. It is 
generally assumed that R&D expenditures are the source of funds for research, 
especially in research-based pharmaceutical companies. With R&D activities, firms 
can improve their performance by focusing on product design and development and 
by improving their manufacturing process, thus product differentiation can be 
obtained (Andras and Srinivasan, 2003). Along with the increasing of investment in 
R&D activity, it will be driving higher R&D intensity.  This supports the hypothesis 
that firms’ amount of R&D expenditure is positively associated with R&D intensity 
obtained by the research-based firms.  
 A positive and statistically significant relationship between log(PROFIT?(-1)) 
and RDI? has also been seen in our calculation (Table 2). This positive relationship 
between firms’ one-year lagged profitability and firms’ R&D intensity means that 
enhancement in firms’ one-year lagged profitability can increase their current R&D 
intensity. Our elasticity estimates suggested that a one percent increase (decrease) in 
firms’ one-year lagged profitability will be accompanied by 0.01 percent increase 
(decrease) in R&D intensity obtained by the firms, at the current year. Based on our 
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previous study (Simanjuntak and Tjandrawinata, 2011), increasing in profitability in 
the previous period may lead to an increase in R&D expenditure, because profitability 
can affect the company’s strategy to invest more in R&D, which in turn will affect 
firm’s expected revenue and further profitability. Based on Schumpeter’s (1934) 
view, larger profit is the main force to stimulate R&D efforts and innovation 
activities, therefore determining the productivity level of the company. In addition, 
Hundley, Carol, and Park (1996) also stated that the allocation of profits into the 
research activities has an important role in a research-based company, which is, as 
one effort to improve R&D, to ensure the long-term viability of the company. 
Therefore, the size of R&D investment is affected by the amount of profitability 
obtained by the company, which will ultimately be affecting firms’ R&D intensity. 
Hypothesis 2 that the firms’ R&D intensity is positively associated with profitability 
obtained by the research-based firms, is therefore also supported. 
 For sales revenue, the results indicate a negative and statistically significant 
relationship between log(SR?(-1)) and RDI?. A negative relationship between firms’ 
one-year lagged of sales revenue and firms’ R&D intensity means that enhancement 
in firms’ one-year lagged sales revenue can increase their current R&D intensity. Our 
elasticity estimates suggested that a one percent increase (decrease) in firms’ one-year 
lagged sales revenue will be accompanied by 0.10 percent decrease (increase) in 
R&D intensity, during the current year. Pharmaceutical companies which have gone 
through M&A expect consolidation of sales and marketing activities and that will 
lead to greater benefits, for example the enhancement of market share which results 
in greater sales revenue. With an increase in sales revenue, the profit obtained by the 
company will increase, and the source of funds for the research will further increase. 
Therefore, this can in turn lead to more investment in research activities to develop 
and produce new drugs of good quality, thus it will easier to get approval from 
regulatory authorities. From R&D intensity of a pharmaceutical company, the 
amounts of the investment spent by pharmaceutical companies for their R&D 
activities will determine the characteristics and the size of that company (Davidson 
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and Greblov, 2005). From the regression results above, the results obtained do not 
appropriate with the theory. The negative signs obtained from the regression above 
indicate two points: firstly, the size of investment in R&D expenditure is less than the 
amount of sales revenue acquired by the firm, and secondly, the acquired firms’ sales 
revenue is greater than the firms’ amount of R&D spending. LaMattina (2011) found 
that pharmaceutical companies which merge currently tend to invest funds smaller 
than before the mergers. Theoretically, it is supposed that companies conducting a 
merger can invest more funds, since there is consolidation in resources. But, 
according to LaMattina’s observation, pharmaceutical companies always invest at 
least 20 percent of their revenue before, but in fact currently their investment into 
R&D has been decreased. It might have happened, due to when  mergers were done, 
the fund derived from their revenue, which was supposed to be allocated to research 
activities, was  used to finance their mergers. Hypothesis 3 that the firms’ sales 
revenue is positively associated with firms’ R&D intensity, obtained by the research-
based firms, is therefore not supported.  
  
4. Conclusion 
The main purpose of this study is to examine the role of lagged R&D 
expenditure, lagged profitability, and lagged sales revenue of research-based 
companies on firms’ amount of R&D intensity on pharmaceutical companies, which 
do M&A. The regression used R&D intensity as the dependent variable, and lagged 
R&D expenditure, lagged profitability, and lagged sales revenue as the independent 
variable. Based upon our fixed effect model specification, we estimate the elasticity 
of R&D intensity, obtained by the firms with respect to the determinants of R&D 
intensity, as the proxy of the firms’ productivity. 
Regression analysis showed that firms’ one-year lagged R&D expenditure (t-
1) and lagged profitability have been positive and affect significantly the firms’ R&D 
intensity in the research-based pharmaceutical companies, except for firms’ one-year 
lagged sales revenue which has been negative and affects significantly the firms’ 
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R&D intensity in the research-based pharmaceutical companies. Thereby, hypotheses 
that firms’ amount of R&D expenditure, profitability, and sales revenue has a positive 
impact on productivity firms which do M&A, are not all proven. 
This model is far from being perfect, because there are many parameters 
which can also directly affect R&D intensity. Another factor that can affect R&D 
intensity according to Chao and Kavadias (2009) studies are R&D return, risk, and 
cost of sales, which lower R&D return, risk, and cost of sales will be driving higher 
R&D intensity, and lower competition intensity will be driving lower R&D intensity 
(consistent with the Schumpeterian Hypotheses). However, the availability of such 
data was strictly limited which hampered us to analyze such additional data. The 
present model is therefore sufficient at any rate, to show the relationship between 
R&D expenditure, profitability, and sales revenue on firms’ productivity, on R&D 
intensity following M&A activities.   
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